Table 1 Baseline characteristics of the intention-to-treat population
|  | Group 1 (n = 16) | Group 2 (n = 15) | All (N = 31) |
|---|---|---|---|
Mean1Â (SD) Age at Enrollment (years) (Range) | 34.2 (7.3) | 32.5 (7.4) | 33.4 (7.3) |
(21–47) | (19–44) |  | |
Mean (SD) Baseline COWS score (Range) | 15.3 (2.7) | 14.5 (2.7) | 14.9 (2.7) |
(10–21) | (9–19) | (9–21) | |
Mean (SD) Duration of Opioid Use (years) (Range) | 12.9 (7.0) | 10.8 (6.4) | 11.8 (6.7) |
(1–27) | (0.5–24.0) |  | |
Mean (SD) Morphine Milligram Equivalent (Range) | 1406.3 (1031.6) | 1209.3 (566.5) | 1311.0 (831.8) |
(300–4000) | (150–2000) | (150–4000) | |
Gender: n (n/N%) | |||
 Female | 6 (37.5%) | 5 (33.3%) | 11 (35.5%) |
 Male | 10 (62.5%) | 10 (66.7%) | 20 (64.5%) |
Race: n (n/N%) | |||
 White | 14 (87.5%) | 12 (80.0%) | 26 (83.9%) |
 Hispanic or Latino | 1 (6.3%) | 3 (20.0%) | 4 (12.9%) |
 Black or African American | 1 (6.3%) | 0 (0%) | 1 (3.2%) |
Psychiatric Co-Morbidities2,3 | |||
 Depression | 4 (25.0%) | 6 (40.0%) | 10 (33.3%) |
 Anxiety | 3 (18.8%) | 7 (46.7%) | 10 (33.3%) |
 Bipolar Disorder | 4 (25.0%) | 4 (26.7%) | 8 (26.7%) |
Opioid Type2,4 | |||
 Heroin | 14 (93.3%) | 13 (86.7%) | 27 (90.0%) |
 Prescription Narcotics | 1 (6.7%) | 4 (26.7%) | 5 (16.7%) |
 Buprenorphine/Naloxone | 1 (6.7%) | 0 (0%) | 1 (3.3%) |
 Methadone | 0 (0%) | 1 (6.7%) | 1 (3.3%) |
 Fentanyl | 0 (0%) | 1 (6.7%) | 1 (3.3%) |
Non-Opioid Drug Use in Previous 30 Days2 | |||
 Alprazolam | 5 (33.3%) | 4 (26.7%) | 9 (30.0%) |
 THC | 3 (20.0%) | 5 (33.3%) | 8 (26.7%) |
 Alcohol | 4 (26.7%) | 5 (33.3%) | 9 (30.0%) |
 Methamphetamine | 5 (33.3%) | 7 (46.7%) | 12 (40.0%) |
 Cocaine | 4 (26.7%) | 2 (13.3%) | 6 (20.0%) |
 Other | 1 26.7%) | 4 (26.7%) | 5 (16.7%) |